This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLYG
Implied Volatility Surging for AMN Healthcare (AMN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AMN Healthcare (AMN) stock based on the movements in the options market lately.
Should Vanguard S&P Small-Cap 600 Growth ETF (VIOG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VIOG
CVS Health's (CVS) New Acquisitions Aid, Cost Woes Linger
by Zacks Equity Research
CVS Health (CVS) launches functionality that gives patients more choices and convenience in filling prescriptions.
Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPSM
Teladoc Health (TDOC) Down 8.1% Since Q4 Earnings Release
by Zacks Equity Research
Teladoc Health's (TDOC) fourth-quarter results bear the brunt of escalating expenses. Management expects 2023 revenues within $2,550-$2,675 million, way higher than the 2022 figure.
IDEXX (IDXX) Global Sales, Instrument Placement Robust
by Zacks Equity Research
IDEXX (IDXX) continues to demonstrate solid growth globally, primarily aided by a gain in CAG and Water businesses.
Select Medical (SEM) Q4 Earnings Miss Estimates, Revenues Up
by Zacks Equity Research
Select Medical (SEM) anticipates 2023 revenues to be within $6.5-$6.7 billion.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Walgreens' (WBA) New Partnerships Aid, Margin Pressure Ails
by Zacks Equity Research
Walgreens Boots (WBA) raises its U.S. Healthcare target, including fiscal 2025 sales goal.
Quest Diagnostics (DGX) Base Business Growth Robust, Volume Up
by Zacks Equity Research
Quest Diagnostics (DGX) starts to benefit from incentives related to these value-based contracts, which help demonstrate the value of these strategic relationships.
Medtronic (MDT) Receives CE Mark Approval For Aurora System
by Zacks Equity Research
Medtronic (MDT) Aurora EV-ICD system indicated for patients at risk of life-threatening arrhythmias.
Pediatrix (MD) Q4 Earnings miss on High Operating Expenses
by Zacks Equity Research
Pediatrix (MD) anticipates 2023 adjusted EBITDA to be within $235-$245 million.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about Neogen's (NEOG) strong performance across its Animal Safety and Food Safety segments.
Here's Why You Should Retain Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) owing to continued growth in the Diabetes business.
Edwards Lifesciences (EW) Gains on Innovation, Margin Growth
by Zacks Equity Research
In Edwards Lifesciences' (EW) Smart Recovery portfolio, the adoption of FloTrac and ClearSight sensors remains strong.
AMN Healthcare (AMN) Q4 Earnings, Revenues Beat Estimates
by Zacks Equity Research
Despite AMN Healthcare's (AMN) robust results in the majority of its segments, it records a soft overall Q4 performance.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues benefiting from its commitment to understand the venous system. However, dependency on the wide adoption of products is a concern.
AMN Healthcare Services (AMN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 14.29% and 5.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
Boston Scientific (BSX) Gains From New Buyouts, Cost Woes Stay
by Zacks Equity Research
Boston Scientific's (BSX) EMEA business grows above market, supported by the company's ongoing investments in emerging markets.
Here's Why You Should Add Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.
Quest Diagnostics (DGX) New Pact to Boost Laboratory Services
by Zacks Equity Research
Quest Diagnostics' (DGX) recent agreement is intended to offer advanced and quality clinical laboratory services in the greater New York region and beyond.
Reasons Why You Should Retain ResMed (RMD) Stock For Now
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) owing to the increased demand for its sleep and respiratory care devices.
Medical Device Stocks' Q4 Earnings on Feb 16: WST, SWAV & More
by Indrajit Bandyopadhyay
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat macro headwinds. Let's see how WST, SWAV, AMN, ITGR and PACB are likely to fare this time.